Exchange: NASDAQ·Updated 07:59 PM EST

KPTI News

News
all
press releases
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS) stockread more...
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS) stockread more...
Benzinga
More News
Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock increased by 17.5% to $0.06 during Friday's after-market session. The company's market cap stands at $1.3 million. Nkarta (NASDAQ:NKTX) stock increased byread more...
Benzinga
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH) Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology...
PR Newswire
Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the FuturePR NewswireNEWTON, Mass., Nov. 2, 2026 The Company Remains Focused on Supporting...
PR Newswire
Aurinia (AUPH) delivered earnings and revenue surprises of +15.00% and -4.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PR NewswireNEWTON, Mass., Oct. 1, 2026NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a...
PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., Sept. 1, 2026 NEWTON, Mass., Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq...
PR Newswire
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis PR Newswire NEWTON, Mass...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PR Newswire NEW YORK, Aug. 27, 2026 NEW YORK, Aug. 27, 2026...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PR Newswire NEW YORK, Aug. 20, 2026 NEW YORK, Aug. 20, 2026...
PR Newswire

Advertisement|Remove ads.